The drug of choice for ventricular arrhythmias due to infarction is amiodarone. Myocardial infarction can develop persistent ventricular arrhythmias, and episodes of arrhythmogenic arrhythmias can exacerbate myocardial damage and increase the infarct size. Therefore, patients should be managed quickly and effectively for ventricular arrhythmias. In the case of hemodynamically stable ventricular arrhythmias, intravenous amiodarone is the treatment of choice because amiodarone is a multichannel blocker that exhibits the electrophysiological effects of all antiarrhythmic drugs. First, it can mildly block sodium channels, especially at fast heart rates, and can perform potent blockade, also without the proarrhythmic effects characteristic of one class of antiarrhythmic drugs. In addition, it can inhibit α and β receptors non-competitively, and it can also dilate coronary arteries, increase blood flow, reduce myocardial oxygen consumption, and increase myocardial perfusion.